StreetInsider.com News Articles

Kymera presents phase 1 data for KT-621 in healthy Japanese adults

Fri, 12 Jun 2026 07:00:25 -0400

Kymera Therapeutics Inc. (NASDAQ: KYMR) presented phase 1 study results for its experimental drug KT-621 in healthy Japanese adults at the Japanese Dermatological Association Annual Meeting in Kyoto.

The randomized, double-blind, placebo-controlled study enrolled 24 healthy Japanese adults across two dose levels, with participants receiving KT-621 or placebo once daily for seven days. The drug demonstrated rapid absorption and dose-proportional increases in plasma exposure, according to the company's statement.

KT-621 achieved median STAT6 degradation of at least 98% at both dose levels by day seven and was well tolerated across both doses. The results were comparable to those observed in previous studies

Kymera presents phase 1 data for KT-621 in healthy Japanese adults

Fri, 12 Jun 2026 07:00:25 -0400

Kymera Therapeutics Inc. (NASDAQ: KYMR) presented phase 1 study results for its experimental drug KT-621 in healthy Japanese adults at the Japanese Dermatological Association Annual Meeting in Kyoto.

KT-621 achieved median STAT6 degradation of at least 98% at both dose levels by day seven and was well tolerated across both doses. The results were comparable to those observed in previous studies

Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting

Fri, 12 Jun 2026 07:00:00 -0400

Oral presentation at JDA features new data from the KT-621 Phase 1 study in healthy Japanese adults, with safety and PK/PD results consistent with previously reported KT-621 clinical studies

KT-621 parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively

WATERTOWN, Mass., June 12, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the results from the Phase

Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting

Fri, 12 Jun 2026 07:00:00 -0400

Oral presentation at JDA features new data from the KT-621 Phase 1 study in healthy Japanese adults, with safety and PK/PD results consistent with previously reported KT-621 clinical studies

KT-621 parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively

Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting

Fri, 12 Jun 2026 07:00:00 -0400

Oral presentation at JDA features new data from the KT-621 Phase 1 study in healthy Japanese adults, with safety and PK/PD results consistent with previously reported KT-621 clinical studies

KT-621 parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively

Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting

Fri, 12 Jun 2026 07:00:00 -0400

Oral presentation at JDA features new data from the KT-621 Phase 1 study in healthy Japanese adults, with safety and PK/PD results consistent with previously reported KT-621 clinical studies

KT-621 parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively

Kymera begins phase 1 trial of KT-485, receives $20M from Sanofi

Tue, 09 Jun 2026 07:00:48 -0400

Kymera Therapeutics Inc. (NASDAQ: KYMR) announced that the first participant has been dosed in a phase 1 clinical trial of KT-485, an oral IRAK4 degrader being developed for immunological diseases. The dosing triggered a $20 million milestone payment from collaboration partner Sanofi.

The phase 1 trial is evaluating KT-485 in healthy volunteers and patients with hidradenitis suppurativa. Sanofi is leading the development, regulatory and commercial efforts for the program under their collaboration agreement.

KT-485 is described as a second-generation oral degrader of IRAK4, a protein involved in inflammatory pathways. The drug targets both kinase and scaffolding functions of IRAK4 through protein degradation.

The

Kymera begins phase 1 trial of KT-485, receives $20M from Sanofi

Tue, 09 Jun 2026 07:00:48 -0400

The

Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration

Tue, 09 Jun 2026 07:00:00 -0400

First-in-human Phase 1 trial evaluating KT-485 (SAR447971) initiated, triggering a $20 million milestone payment from Sanofi

WATERTOWN, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the first participant has been dosed in the first-in-human Phase 1 clinical trial evaluating KT-485 (SAR447971), an oral, potent and selective IRAK4 degrader, in adult healthy volunteers and hidradenitis suppurativa (HS) patients. The Phase 1 trial (NCT07629336) is being conducted by the

Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration

Tue, 09 Jun 2026 07:00:00 -0400

First-in-human Phase 1 trial evaluating KT-485 (SAR447971) initiated, triggering a $20 million milestone payment from Sanofi

Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration

Tue, 09 Jun 2026 07:00:00 -0400

First-in-human Phase 1 trial evaluating KT-485 (SAR447971) initiated, triggering a $20 million milestone payment from Sanofi

Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration

Tue, 09 Jun 2026 07:00:00 -0400

First-in-human Phase 1 trial evaluating KT-485 (SAR447971) initiated, triggering a $20 million milestone payment from Sanofi

Form 8-K Kymera Therapeutics, For: Jun 05

Mon, 08 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260608/26617245.html

Form 8-K Kymera Therapeutics, For: Jun 05

Mon, 08 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260608/26617245.html

Kymera Therapeutics names Penny Carlson development operations head